PARP pharmacologic inhibition represents a major factor in treating ovarian cancer with mutations in the BRCA; inhibition of PARP enhances ferroptosis through suppressing SLC7A11 and synergizes with ferroptosis inducers within BRCA-proficient ovarian cancer [49]. This evidence concerns the gene SLC7A11 and ovarian carcinoma.